StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) stock

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.48−0.03 (-5.42%)

Close on Nov 17, 2026Market cap $73.93MP/E –Yield –

Coherus Oncology pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Coherus Oncology's pe ratio was 1.2× on Jul 31, 2026, against 0.5× a year earlier. Over the last 3 years it ranged from 0.3× to 15.7×, with a median of 4.1×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jul 31, 20261.2×+0.8
2025Dec 31, 20250.3×−8.8
2021Apr 30, 20219.1×+0.6
2020Dec 31, 20208.5×–

More Coherus Oncology figures

See a number that looks wrong?